<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02511652</url>
  </required_header>
  <id_info>
    <org_study_id>HBarcelona</org_study_id>
    <nct_id>NCT02511652</nct_id>
  </id_info>
  <brief_title>Ambu AuraGain vs LMA Supreme in Laparoscopic Surgery</brief_title>
  <official_title>Comparison of the Ambu AuraGain vs. LMA Supreme in Paralysed Patients Undergoing Gynecologic Laparoscopic Surgery in the Trendelemburg Position</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ambu A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the performance of two supraglottic airway devices (SGA),&#xD;
      the new Ambu AuraGain and the LMA Supreme, in sixty female patients undergoing gynaecologic&#xD;
      laparoscopy in the trendelemburg position.&#xD;
&#xD;
      Primary outcome is the airway seal pressure. Secondary outcomes are ease of insertion,&#xD;
      quality of ventilation, endoscopic view of the glottis, gastric tube passage and&#xD;
      complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients are randomly assigned to 2 groups:&#xD;
&#xD;
        -  Group 1: Ambu AuraGain.&#xD;
&#xD;
        -  Group 2: LMA Supreme, Teleflex&#xD;
&#xD;
      Procedure:&#xD;
&#xD;
      The investigation protocol contains the following sections:&#xD;
&#xD;
        1. Induction of anaesthesia. Intravenous infusion of remifentanil and propofol targeting&#xD;
           the effect site (2-4 ng/ml and 4-6 µg/ml respectively). No muscle relaxant will be used&#xD;
           for insertion of the SGA. Rocuronium 0.2 mg/Kg will be administered before initiation of&#xD;
           pneumoperitoneum.&#xD;
&#xD;
        2. Insertion of the SGAs. The size of the SGA device used is based on the manufacturers'&#xD;
           recommendations. All devices are deflated a lubricated prior to use. Once inserted, the&#xD;
           cuff is be inflated with a manometer up to 60 cm H20 Position of the device is adjusted&#xD;
           if needed. Data recorded: size of SGA, time an number of attempts.&#xD;
&#xD;
        3. Fibreoptic evaluation of the SGAs anatomical position: complete view of the vocal cords&#xD;
           (I), epiglottis visible inside, but not causing obstruction (II), epiglottis visible and&#xD;
           obstructing the glottic inlet (III), or glottic structures not identified (IV).&#xD;
&#xD;
        4. Functionality of the gastric drainage channel of the SGAs: passage of a 16 G size tube.&#xD;
&#xD;
        5. Measurement of airway seal pressure (oropharyngeal leak pressure (OLP): at baseline, and&#xD;
           at 15, 30 and 60 minutes. The maximum pressure allowed is 40 cm H2O.&#xD;
&#xD;
        6. Ventilatory mechanics and parameters are measured at baseline, and at 15, 30 and 60&#xD;
           minutes.&#xD;
&#xD;
           Perioperative complications: Hiccup, gastric distension, regurgitation / Aspiration,&#xD;
           airway obstruction, laryngospasm, dental, mucosal or tongue injury, hypoxia (SpO2 &lt; 92%)&#xD;
&#xD;
        7. Removal of the SGAs: Presence of blood - 3 level grading (+/++/+++) Postoperative&#xD;
           complications: sore throat, hoarseness, dysphonia, dysphagia, dysphagia: 3-point scale&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Airway seal pressure</measure>
    <time_frame>At 15 minutes</time_frame>
    <description>Maximum airway pressure that the device can achieve without oropharyngeal leak of gas.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ease of insertion of the device</measure>
    <time_frame>Baseline</time_frame>
    <description>Time needed to insert the device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of ventilation</measure>
    <time_frame>At baseline and at 15, 30 and 60 minutes</time_frame>
    <description>number of manoeuvres/corrections required</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic view of glottic structures</measure>
    <time_frame>At 15 minutes</time_frame>
    <description>Assessment of alignment with the glottic inlet as: complete view of the vocal cords (I), epiglottis visible inside, but not causing any obstruction (II), epiglottis visible and causing obstruction (III) or glottis not identified (IV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric tube insertion</measure>
    <time_frame>At 5 minutes</time_frame>
    <description>Ease of passage of a gastric tube as: easy, difficult or impossible</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of perioperative complications</measure>
    <time_frame>2 hours</time_frame>
    <description>number of patients with adverse events: Airway obstruction, desaturation, Aspiration, oropharyngeal trauma, sore throat</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Laparoscopy</condition>
  <condition>Airway Management</condition>
  <condition>Supraglottic Airway Devices</condition>
  <arm_group>
    <arm_group_label>Ambu AuraGain</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insertion of the supraglottic device and evaluation of its clinical performance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LMA Supreme</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insertion of the supraglottic device and evaluation of its clinical performance</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ambu AuraGain evaluation</intervention_name>
    <description>Evaluation of clinical performance in terms of Insertion, ventilation, position and complications</description>
    <arm_group_label>Ambu AuraGain</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LMA Supreme evaluation</intervention_name>
    <description>Evaluation of clinical performance in terms of Insertion, ventilation, position and complications</description>
    <arm_group_label>LMA Supreme</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic surgery</intervention_name>
    <description>Gynecologic laparoscopic surgery in the trendelemburg position</description>
    <arm_group_label>Ambu AuraGain</arm_group_label>
    <arm_group_label>LMA Supreme</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients evaluated as eligible for a SGA&#xD;
&#xD;
          -  ASA I-III&#xD;
&#xD;
          -  Without criteria for difficult airway&#xD;
&#xD;
          -  Body Mass Index ≤ 35 kg/m2&#xD;
&#xD;
          -  The patient has signed the Informed Consent&#xD;
&#xD;
          -  The patient understands his or hers rights and consequences related to this&#xD;
             investigation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Planned operation time &gt; 2 hours&#xD;
&#xD;
          -  High risk of regurgitation&#xD;
&#xD;
          -  Respiratory tract pathology&#xD;
&#xD;
          -  Preoperative sore throat&#xD;
&#xD;
          -  Patients with a known or predicted difficult airway&#xD;
&#xD;
          -  Patients diagnosed with dementia or any mental handicaps&#xD;
&#xD;
          -  Patient who has a guardian.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana M Lopez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ambulatory Surgery, Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>July 20, 2015</study_first_submitted>
  <study_first_submitted_qc>July 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2015</study_first_posted>
  <last_update_submitted>February 19, 2016</last_update_submitted>
  <last_update_submitted_qc>February 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Ana M Lopez</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

